Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatment
Research and development of RNA-based diagnostics and therapeutics; Research and development of RNA-based diagnostics and therapeutics for the diagnosis and treatment of psychiatric and neurological diseases; Research and development of RNA biomarkers for the diagnosis and treatment of psychiatric and neurological diseases; Research and development of RNA biomarkers for the diagnosis and treatment of depression; Research and development of RNA-based diagnostic assays; Research and development of RNA-based diagnostic tests to diagnose and treat psychiatric and neurological diseases; Research and development of RNA-based diagnostic tests for depression
Class 042: Research and development of RNA-based diagnostics and therapeutics; Research and development of RNA-based diagnostics and therapeutics for the diagnosis and treatment of psychiatric and neurological diseases; Research and development of RNA biomarkers for the diagnosis and treatment of psychiatric and neurological diseases; Research and development of RNA biomarkers for the diagnosis and treatment of depression; Research and development of RNA-based diagnostic assays; Research and development of RNA-based diagnostic tests to diagnose and treat psychiatric and neurological diseases; Research and development of RNA-based diagnostic tests for depression
Cookie Preferences
We use cookies (including Google Analytics) to improve our site and understand how visitors use it.
